SCHEMBL1653008

SCHEMBL1653008

O=C(c1ccccc1)c1ccc(F)c(Cl)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.57
RAB9A P51151 5/20 0.57
ATM Q13315 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
SRD5A2 P31213 3/20 0.55
VCAM1 P19320 1/20 0.53
ALDH1A1 P00352 1/20 0.52
HSD17B1 P14061 1/20 0.50
HSD17B2 P37059 1/20 0.50
PDK1 Q15118 2/20 0.49
PDK2 Q15119 2/20 0.49
PDK3 Q15120 2/20 0.49
PDK4 Q16654 2/20 0.49
CNR2 P34972 2/20 0.47
CNR1 P21554 1/20 0.47
HSD17B14 Q9BPX1 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
PBRM1 Q86U86 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10399614 0.90 SRD5A2 (0.53) NPC1RAB9ASRD5A2VCAM1HSD17B1
SCHEMBL7813949 0.87 ACHE (0.49) NPC1RAB9AL3MBTL1SRD5A2VCAM1
SCHEMBL1651161 0.87 SRD5A2 (0.52) NPC1RAB9ASRD5A2ALDH1A1HSD17B1
SCHEMBL20555530 0.86 SRD5A2 (0.62) NPC1RAB9AATMTDP1L3MBTL1
SCHEMBL6584544 0.85 VCAM1 (0.57) NPC1RAB9AATMTDP1L3MBTL1
SCHEMBL10398542 0.85 SRD5A2 (0.63) NPC1RAB9ASRD5A2VCAM1HSD17B1
Water SCHEMBL27654072 0.84 VCAM1 (0.55) NPC1RAB9AATMTDP1L3MBTL1
SCHEMBL333237 0.82 SRD5A2 (0.78) NPC1RAB9AATMTDP1L3MBTL1
SCHEMBL332679 0.82 ATM (0.61) NPC1RAB9AATMTDP1L3MBTL1
SCHEMBL7813946 0.81 HAO1 (0.46) NPC1RAB9AL3MBTL1SRD5A2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114130212-B Method for preparing separation membrane by using small molecular monomers 天津工业大学 2025-02-21 CN claimed
CN-118599118-A Energy-saving and consumption-reducing poly (ether) sulfone and method for synthesizing block copolymer thereof 山东净泽膜科技有限公司 2024-09-06 CN claimed
CN-117384385-A Polysulfone-based block copolymer with nonlinear block structure, and synthetic method and application thereof 天津工业大学 2024-01-12 CN claimed
CN-117264215-A Method for synthesizing polysulfone, polyether sulfone and segmented copolymer thereof by dehydration synchronous polymerization 天津工业大学 2023-12-22 CN claimed
CN-114130212-A Method for preparing separation membrane by using small molecule monomer 天津工业大学 2022-03-04 CN claimed
CN-107805305-B Industrial synthesis method of membrane-grade polyarylethersulfone resin 江门市优巨新材料有限公司 2020-10-27 CN claimed
CN-114130212-B Method for preparing separation membrane by using small molecular monomers 天津工业大学 2025-02-21 CN disclosed
CN-118599118-A Energy-saving and consumption-reducing poly (ether) sulfone and method for synthesizing block copolymer thereof 山东净泽膜科技有限公司 2024-09-06 CN disclosed
CN-117384385-B Polysulfone-based block copolymer with nonlinear block structure, and synthetic method and application thereof 天津工业大学 2024-03-22 CN disclosed
CN-117384385-A Polysulfone-based block copolymer with nonlinear block structure, and synthetic method and application thereof 天津工业大学 2024-01-12 CN disclosed
CN-117264215-A Method for synthesizing polysulfone, polyether sulfone and segmented copolymer thereof by dehydration synchronous polymerization 天津工业大学 2023-12-22 CN disclosed
CN-110903480-B Preparation method of controllable molecular weight polysulfone 万华化学集团股份有限公司 2022-04-22 CN disclosed
CN-114130212-A Method for preparing separation membrane by using small molecule monomer 天津工业大学 2022-03-04 CN disclosed
US-20080293775-A1 Substituted Diphenylethers, -Amines, -Sulfides and -Methanes for the Treatment of Respiratory Disease ASTRAZENECA AB (SE) 2008-11-27 US disclosed
EP-1963259-A2 SUBSTITUTED DIPHENYLETHERS, -AMINES, -SULFIDES AND -METHANES FOR THE TREATMENT OF RESPIRATORY DISEASE AstraZeneca AB (SE) 2008-09-03 EP disclosed
EP-1937632-A1 NOVEL COMPOUNDS Astra Zeneca AB (SE) 2008-07-02 EP disclosed
WO-2007068894-A2 SUBSTITUTED DIPHENYLETHERS, -AMINES, -SULFIDES AND -METHANES FOR THE TREATMENT OF RESPIRATORY DISEASE ASTRAZENECA AB (SE) 2007-06-21 WO disclosed
WO-2007039736-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2007-04-12 WO disclosed
EP-0600318-B1 Asymmetric, halogenated benzophenones and process for their preparation CLARIANT GMBH (DE) 1998-04-08 EP disclosed
EP-0600318-A1 Asymmetric, halogenated benzophenones and process for their preparation HOECHST AKTIENGESELLSCHAFT (DE) 1994-06-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293775-A1 Substituted Diphenylethers, -Amines, -Sulfides and -Methanes for the Treatment of Respiratory Disease PNMT, SQOR, SMS NPC1 2239/4885RAB9A 3617/4885ATM 356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.